Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
Emergent BioSolutions (NYSE: EBS) will hold a conference call on July 30, 2020, at 5:00 pm ET to discuss Q2 2020 financial results and provide revenue guidance for Q3 and the full year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) will hold a conference call on July 30, 2020, at 5:00 pm ET to discuss Q2 2020 financial results and provide revenue guidance for Q3 and the full year. The call can be accessed via telephone or webcast. Investors can view the live feed through the company’s website.
Emergent is focused on enhancing public health through innovative life sciences solutions, with a mission to protect 1 billion lives by 2030.
Positive
- Scheduled conference call to discuss Q2 2020 financial results indicates transparency and ongoing communication with investors.
- Revenue guidance for Q3 2020 and full year could signal positive growth expectations.
Negative
- None.
Details
News Market Reaction – EBS
The recorded move for EBS in the trading session of this news was +1.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., July 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.
This conference call can be accessed live by telephone or by webcast:
| Live Teleconference Information: Dial in number: (855) 766-6521 International dial in number: (262) 912-6157 Conference ID: 7380905 Live Webcast Information: Visit https://edge.media-server.com/mmc/p/bkkqx6kk for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com
Media Contact:
Miko B. Neri
Senior Director, Corporate Communications
240-631-3392
NeriM@ebsi.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.